Jazz Pharmaceuticals plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Jazz Pharmaceuticals plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $476.46M | Feb 26, 2019 |
| FY2018 | Sep 30, 2018 | $469.37M | Feb 26, 2019 |
| FY2018 | Jun 30, 2018 | $500.48M | Feb 26, 2019 |
| FY2018 | Mar 31, 2018 | $444.61M | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $436.40M | Feb 26, 2019 |
| FY2018 | Sep 30, 2017 | $411.86M | Feb 26, 2019 |
| FY2018 | Jun 30, 2017 | $394.39M | Feb 26, 2019 |
| FY2018 | Mar 31, 2017 | $376.05M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $396.62M | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $374.18M | Feb 27, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.27B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.07B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $3.83B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $3.66B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $3.09B | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $665.52M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $600.89M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $562.44M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $534.73M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $581.74M | Feb 23, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $611.15M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $554.85M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $530.20M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | $501.55M | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $541.18M | Feb 23, 2021 |
| FY2020 | Sep 30, 2019 | $500.92M | Feb 23, 2021 |
| FY2020 | Jun 30, 2019 | $495.75M | Feb 23, 2021 |
| FY2020 | Mar 31, 2019 | $469.83M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $441.00M | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $438.62M | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($356.15M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $560.12M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $414.83M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($224.06M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | ($329.67M) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $133.41M | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | $148.23M | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | $114.80M | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | ($157.83M) | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | $73.99M | Feb 23, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($430.24M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $716.63M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $578.58M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | ($65.53M) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $170.28M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $378.07M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $532.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $614.84M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $528.84M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $591.65M | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $299.73M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $226.62M | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $198.44M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $162.30M | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $135.25M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $85.18M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $41.63M | Feb 23, 2016 |
| FY2014 | Dec 31, 2012 | $20.48M | Feb 24, 2015 |
| FY2013 | Dec 31, 2011 | $14.12M | Feb 25, 2014 |
| FY2012 | Dec 31, 2010 | $25.61M | Feb 26, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.81B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.34B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.42B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $1.45B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $854.23M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $736.94M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $683.53M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $544.16M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $502.89M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.40B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.09B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.27B | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $778.51M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $899.65M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $776.40M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $798.90M | Feb 23, 2021 |
| FY2019 | Dec 31, 2017 | $693.09M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $592.39M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.75M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $38.07M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $23.96M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $29.05M | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | $27.64M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $15.00M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $40.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $20.37M | Feb 23, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.66B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $12.01B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.39B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $10.84B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $12.30B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $6.54B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $5.54B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $5.20B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $5.12B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $4.80B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.32B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.09B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $3.74B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $3.09B | Feb 24, 2026 |
| FY2024 | Dec 31, 2021 | $3.97B | Feb 26, 2025 |
| FY2023 | Dec 31, 2020 | $3.66B | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | $3.11B | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $2.76B | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $2.71B | Feb 23, 2021 |
| FY2019 | Dec 31, 2016 | $1.88B | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.72B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.75B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $1.69B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.83B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $958.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $920.02M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $927.63M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $947.54M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $893.81M | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $646.18M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $878.66M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $733.59M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $830.23M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.16B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.07B | Feb 23, 2021 |
| FY2019 | Jan 1, 2019 | $845.90M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $841.05M | Feb 25, 2020 |
| FY2018 | Jan 1, 2018 | $917.62M | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.41B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.51B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $881.48M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $591.45M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $1.06B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $637.34M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $309.62M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $386.04M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $365.96M | Feb 26, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.36B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.11B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.71B | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | $5.72B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $6.05B | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $2.09B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.61B | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | $1.60B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.58B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $2.03B | Feb 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 9 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 6 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | 2 | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | (2) | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 8 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 6 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 26, 2025 |
| FY2023 | Dec 31, 2021 | (5) | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 23, 2021 |
| FY2020 | Sep 30, 2020 | 2 | Feb 23, 2021 |
| FY2020 | Jun 30, 2020 | 2 | Feb 23, 2021 |
| FY2020 | Mar 31, 2020 | (2) | Feb 23, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 23, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61.44M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 60.63M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 62.26M | Feb 26, 2025 |
| FY2023 | Dec 31, 2022 | 63.21M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 61.63M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 56.17M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 56.14M | Feb 23, 2021 |
| FY2019 | Dec 31, 2018 | 57.70M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 58.90M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 59.82M | Feb 27, 2018 |